<DOC>
	<DOCNO>NCT00244114</DOCNO>
	<brief_summary>Based find anaphylactic reaction Benefix ( `` FIX '' ) associate specific IgE , Basophil histamine release assay select evaluate demonstrate subject sensitization FIX .</brief_summary>
	<brief_title>Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<criteria>Study Group : Written inform consent assent , applicable . Subjects moderate severe Hemophilia B ( FIX : C &lt; 5 % ) , report class II class III allergic manifestation within 24 hour BeneFIX infusion . Control Group : Written inform consent assent , applicable . Subjects moderate severe Hemophilia B ( FIX : C &lt; 5 % ) Study group : Subjects reaction rechallenged BeneFIX , absence prophylactic immunomodulating therapy . Subjects whose recent allergic manifestation BeneFIX occur &gt; 36 month prior provide write informed consent study . Subjects take antihistamine , steroidal , immunosuppressive therapy within 72 hour schedule visit study . Subjects immune disorder . Subjects unable comply minimum 5day FIX washout requirement . Control group : Subjects document evidence prior allergic reaction FIX product . Subjects document evidence prior current FIX inhibitor ( BU &gt; 0.6 ) . Subjects take antihistamine , steroidal , immunosuppressive therapy within 72 hour schedule study blood draw . Subjects immune disorder . Subjects unable comply minimum 5day FIX washout requirement .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Hemophilia B</keyword>
	<keyword>Allergic Reaction</keyword>
</DOC>